Lansoprazole sulfone (BioDeep_00000033177)
human metabolite Endogenous blood metabolite
代谢物信息卡片
化学式: C16H14F3N3O3S (385.0707930000001)
中文名称: 右旋兰索拉唑杂质B
谱图信息:
最多检出来源 Homo sapiens(blood) 50%
分子结构信息
SMILES: CC1=C(C=CN=C1CS(=O)(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
InChI: InChI=1S/C16H14F3N3O3S/c1-10-13(20-7-6-14(10)25-9-16(17,18)19)8-26(23,24)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
描述信息
Lansoprazole sulfone is only found in individuals that have used or taken Lansoprazole. Lansoprazole sulfone is a metabolite of Lansoprazole. Lansoprazole sulfone belongs to the family of Sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
同义名列表
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 10385385
- HMDB: HMDB0014009
- ChEMBL: CHEMBL4520193
- chemspider: 8560827
- CAS: 131926-99-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Dan Zhang, Yanan Zhang, Man Liu, Xiaolin Wang, Man Yang, Jing Han, Huichen Liu. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects.
European journal of drug metabolism and pharmacokinetics.
2013 Sep; 38(3):209-15. doi:
10.1007/s13318-012-0115-8. [PMID: 23229306] - Dan Zhang, Man Yang, Man Liu, Yanan Zhang, Xiaolin Wang, Xue Xiao, Huichen Liu. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects.
Xenobiotica; the fate of foreign compounds in biological systems.
2012 Nov; 42(11):1156-62. doi:
10.3109/00498254.2012.687119. [PMID: 22612620] - Dan Zhang, Xiaolin Wang, Man Yang, Guocai Wang, Huichen Liu. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.
Xenobiotica; the fate of foreign compounds in biological systems.
2011 Jun; 41(6):511-7. doi:
10.3109/00498254.2011.559556. [PMID: 21521077] - Hong-Rong Xu, Wei-Li Chen, Xue-Ning Li, Nan-Nan Chu. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.
Pharmaceutical biology.
2010 Aug; 48(8):947-52. doi:
10.3109/13880200903300220. [PMID: 20673183] - Min Song, Xuan Gao, Taijun Hang, Aidong Wen. Simultaneous determination of lansoprazole and its metabolites 5'-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers.
Journal of pharmaceutical and biomedical analysis.
2008 Dec; 48(4):1181-6. doi:
10.1016/j.jpba.2008.08.034. [PMID: 18945568] - M Miura, H Kagaya, H Tada, T Uno, N Yasui-Furukori, T Tateishi, T Suzuki. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
Xenobiotica; the fate of foreign compounds in biological systems.
2006 Jan; 36(1):95-102. doi:
10.1080/00498250500485065. [PMID: 16507515] - Masatomo Miura, Hitoshi Tada, Norio Yasui-Furukori, Tsukasa Uno, Kazunobu Sugawara, Tomonori Tateishi, Toshio Suzuki. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
British journal of clinical pharmacology.
2005 Jul; 60(1):61-8. doi:
10.1111/j.1365-2125.2005.02381.x. [PMID: 15963095] - Masato Saito, Norio Yasui-Furukori, Tsukasa Uno, Takenori Takahata, Kazunobu Sugawara, Akihiro Munakata, Tomonori Tateishi. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
British journal of clinical pharmacology.
2005 Mar; 59(3):302-9. doi:
10.1111/j.1365-2125.2004.02329.x. [PMID: 15752376] - Tsukasa Uno, Norio Yasui-Furukori, Takenori Takahata, Kazunobu Sugawara, Tomonori Tateishi. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Feb; 816(1-2):309-14. doi:
10.1016/j.jchromb.2004.11.052. [PMID: 15664363] - M Miura, H Tada, N Yasui-Furukori, T Uno, K Sugawara, T Tateishi, T Suzuki. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
European journal of clinical pharmacology.
2004 Nov; 60(9):623-8. doi:
10.1007/s00228-004-0809-1. [PMID: 15448955] - Norio Yasui-Furukori, Masato Saito, Tsukasa Uno, Takenori Takahata, Kazunobu Sugawara, Tomonori Tateishi. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Journal of clinical pharmacology.
2004 Nov; 44(11):1223-9. doi:
10.1177/0091270004269015. [PMID: 15496639] - Masatomo Miura, Hitoshi Tada, Toshio Suzuki. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2004 May; 804(2):389-95. doi:
10.1016/j.jchromb.2004.01.057. [PMID: 15081934] - Kaushik Biswas, Uday Bandyopadhyay, Ishita Chattopadhyay, Archana Varadaraj, Esahak Ali, Ranajit K Banerjee. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical.
The Journal of biological chemistry.
2003 Mar; 278(13):10993-1001. doi:
10.1074/jbc.m210328200. [PMID: 12529378] - Hideki Ushiama, Hirotoshi Echizen, Shinobu Nachi, Akihiro Ohnishi. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Clinical pharmacology and therapeutics.
2002 Jul; 72(1):33-43. doi:
10.1067/mcp.2002.125559. [PMID: 12152002] - K Masa, K Arimori, T Nakayama, S Miyamoto, J Fujii, M Nakano. Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.
Biological & pharmaceutical bulletin.
1999 May; 22(5):504-9. doi:
10.1248/bpb.22.504. [PMID: 10375172] - D R Sohn, J T Kwon, H K Kim, T Ishizaki. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Clinical pharmacology and therapeutics.
1997 May; 61(5):574-82. doi:
10.1016/s0009-9236(97)90137-5. [PMID: 9164419]